More stocks to consider
Alternative stocks to Staidson Beijing Biopharmaceuticals (SZSE:300204)


These are the alternatives to Staidson Beijing Biopharmaceuticals that fall within the same industry, Biotechnology, or region, China.

How to read the ranks

For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. The higher the rank, the better the stock performs than its peers. And, we do this for six investment strategies:

Value - shows how good of a value the stock is. Green is "inexpensive"; red is "expensive".

Growth - shows a company's growth potential. Green is "high growth" expected; red is "tough times ahead".

Safety - relates to the amount of debt a company has. Green is low debt level; red is high debt level.

Combined Financial - this isn't an average of the first three ranks but rather a consolidated view across several financial indicators. Green = good; red = tread carefully.

(NEW) Sentiment - quantifies professional analyst ratings and holdings as well as market pulse. Green = positive sentiment; red = skepticism (Only available to Premium Subscribers).

(NEW) 360° View - the ultimate rating with all financial and non-financial indicators.

See Staidson Beijing Biopharmaceuticals Performance

Staidson Beijing Biopharmaceuticals stock research in summary

staidson.com


Staidson Beijing Biopharmaceuticals stock research analysis by the purely faced based Obermatt method on current and historical performance by investment strategy | Staidson Beijing Biopharmaceuticals (SZSE:300204), Biotechnology, China


Latest Obermatt Ranks


Log in or sign up to see the new 360° View and Sentiment ranks.

Country China
Industry Biotechnology
Index
Size class Medium

Large companies - similar industry as Staidson Beijing Biopharmaceuticals

Similar Stocks VALUEVVV GROWTHVV SAFETYVV COMBINED
1. Sun Pharmaceuticals (XL, IN)  Pharmaceuticals
1. Sun Pharmaceuticals (XL, IN)   Pharmaceuticals 35 51 63 49
2. IHH Healthcare (XL, MY)  Health Care Facilities
2. IHH Healthcare (XL, MY)   Health Care Facilities 49 73 13 41

July 24, 2025

Why popular stocks have low ratings

It’s easier said than done. When your stock drops, it’s easy to want to sell it and find a better performer. Think twice, or even three times, before trading. Those fees (especially the hidden ones) can eat up your gains.

Large companies - similar region as Staidson Beijing Biopharmaceuticals

Similar Stocks VALUEVVV GROWTHVV SAFETYVV COMBINED
1. Vodacom (XL, ZA)  Wireless Telecommunication
1. Vodacom (XL, ZA)   Wireless Telecommunication 67 93 69 91
2. Ambev (XL, BR)  Brewers
2. Ambev (XL, BR)   Brewers 59 81 70 88
3. Suzano (XL, BR)  Paper Products
3. Suzano (XL, BR)   Paper Products 83 75 37 82
4. Astra International (XL, ID)  Automobile Manufacturers
4. Astra International (XL, ID)   Automobile Manufacturers 85 17 85 80
5. MTN (XL, ZA)  Wireless Telecommunication
5. MTN (XL, ZA)   Wireless Telecommunication 67 100 42 79
6. Tech Mahindra (XL, IN)  IT Consulting & oth. Services
6. Tech Mahindra (XL, IN)   IT Consulting & oth. Services 55 69 56 76
7. Vale (XXL, BR)  Steel
7. Vale (XXL, BR)   Steel 86 43 58 76
8. Brookfield Business Partners (XL, BM)  Industrial Conglomerates
8. Brookfield Business Partners (XL, BM)   Industrial Conglomerates 59 89 30 73
9. AngloGold Ashanti (XL, ZA)  Gold Production
9. AngloGold Ashanti (XL, ZA)   Gold Production 46 89 54 71
10. Infosys (XXL, IN)  IT Consulting & oth. Services
10. Infosys (XXL, IN)   IT Consulting & oth. Services 43 61 67 67

July 24, 2025


Find more stock ideas
Use your own criteria to filter for stocks or sign up for the latest Top 10 Stock tips.
Log in or Sign up

Mid sized companies - similar industry as Staidson Beijing Biopharmaceuticals

Similar Stocks VALUEVVV GROWTHVV SAFETYVV COMBINED
1. Kalbe Farma (M, ID)  Pharmaceuticals
1. Kalbe Farma (M, ID)   Pharmaceuticals 79 53 96 100
2. Aurobindo Pharma (M, IN)  Pharmaceuticals
2. Aurobindo Pharma (M, IN)   Pharmaceuticals 77 63 81 97
3. Cipla (L, IN)  Pharmaceuticals
3. Cipla (L, IN)   Pharmaceuticals 61 57 98 96
4. Hapvida Participações e Investimentos (M, BR)  Health Care Managed
4. Hapvida Participações e Investimentos (M, BR)   Health Care Managed 91 35 49 81
5. Rede D'Or São Luiz (M, BR)  Health Care Facilities
5. Rede D'Or São Luiz (M, BR)   Health Care Facilities 77 73 38 80
6. Lupin (M, IN)  Pharmaceuticals
6. Lupin (M, IN)   Pharmaceuticals 55 73 56 70
7. Ipca Laboratories (M, IN)  Pharmaceuticals
7. Ipca Laboratories (M, IN)   Pharmaceuticals 49 69 57 66
8. Netcare (M, ZA)  Health Care Facilities
8. Netcare (M, ZA)   Health Care Facilities 87 67 15 64
9. Fleury (M, BR)  Health Care Services
9. Fleury (M, BR)   Health Care Services 96 30 35 57
10. Aspen Pharmacare (M, ZA)  Pharmaceuticals
10. Aspen Pharmacare (M, ZA)   Pharmaceuticals 99 3 42 42

July 24, 2025


Mid sized companies - similar region as Staidson Beijing Biopharmaceuticals

Similar Stocks VALUEVVV GROWTHVV SAFETYVV COMBINED
1. Lojas Renner (M, BR)  Apparel Retail
1. Lojas Renner (M, BR)   Apparel Retail 65 97 92 100
2. Kalbe Farma (M, ID)  Pharmaceuticals
2. Kalbe Farma (M, ID)   Pharmaceuticals 79 53 96 100
3. Alliance Global Group (L, PH)  Industrial Conglomerates
3. Alliance Global Group (L, PH)   Industrial Conglomerates 91 65 72 100
4. Tiger Brands (M, ZA)  Packaged Foods & Meats
4. Tiger Brands (M, ZA)   Packaged Foods & Meats 47 100 90 100
5. Telkom (M, ZA)  Integrated Telecommunication
5. Telkom (M, ZA)   Integrated Telecommunication 97 75 84 98
6. Copa Holdings, (L, PA)  Airlines
6. Copa Holdings, (L, PA)   Airlines 93 71 79 98
7. Maruti Suzuki (L, IN)  Automobile Manufacturers
7. Maruti Suzuki (L, IN)   Automobile Manufacturers 81 57 77 98
8. Colbún (M, CL)  Power Producers & Traders
8. Colbún (M, CL)   Power Producers & Traders 60 94 94 98
9. Harmony (L, ZA)  Gold Production
9. Harmony (L, ZA)   Gold Production 62 91 75 98
10. Aurobindo Pharma (M, IN)  Pharmaceuticals
10. Aurobindo Pharma (M, IN)   Pharmaceuticals 77 63 81 97

July 24, 2025



Obermatt Portfolio Performance
We’re so convinced about our research, that we buy our stock tips.
See the performance of the Obermatt portfolio.